Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Emergent BioSolutions Inc.
DescriptionFusion of CTLA4 and IL10
Molecular Target CD80 (B7-1) ; Interleukin-10 (IL-10) receptor
Mechanism of Action 
Therapeutic ModalityBiologic: Fusion protein
Latest Stage of DevelopmentPreclinical
Standard Indication Autoimmune (unspecified)
Indication DetailsTreat autoimmune disorders
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today